Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Olympus

Manufactures optical and digital equipment for the healthcare and consumer electronics sectors, including endoscopy a... read more Featured Products: More products

Download Mobile App




CHI3L1 Protein Differentially Expressed in Appendicitis and Appendix Carcinomas

By LabMedica International staff writers
Posted on 06 Dec 2022

Appendicitis is inflammation of the appendix. Symptoms commonly include right lower abdominal pain, nausea, vomiting, and decreased appetite. However, approximately 40% of people do not have these typical symptoms. Adenocarcinoma of the appendix is an epithelial cancer of the appendix.

Chitinase-3-like protein 1 (CHI3L1) is a 40-kDa heparin-and-chitin binding glycoprotein, mainly produced by some cell types, including colonic epithelial cells (CECs) chondrocytes, osteosarcoma cells, macrophages, smooth muscle cells, and neutrophils. High levels of CHI3L1 are associated with poor prognosis and accelerate the proliferation of colon cancer cells.

Clinical Laboratorians at The Affiliated Taian City Central Hospital of Qingdao University (Taian, China) collected blood and appendix samples from 46 acute appendicitis and 14 appendix carcinomas that had surgery at the hospital between May 2019 and November 2021. The patients were divided the acute appendicitis group into acute uncomplicated appendicitis (AUA), suppurative appendicitis (SA), and gangrenous appendicitis (GA). The appendix carcinoma group was divided into appendiceal neuroendocrine neoplasms (ANENs) and appendiceal mucinous neoplasms (AMN). Controls were 32 healthy donors.

The patients' venous blood samples were taken before the appendectomy. Blood neutrophil to lymphocyte ratio (NLR), CHI3L1, C-reactive protein (CRP), interleukin-6 (IL-6, Shenzhen Lifotronic Biotech Co. Ltd, Shenzhen, China), and serum amyloid A (SAA, Upper Bio-TECH Pharma Co. Ltd, Shanghai, China) were measured. NLR was analyzed from a blood routine test. For immunohistochemical staining, sections were rinsed in distilled water three times, and the Quick Antigen Retrieval Solution (Beyotime Biotechnology, Haimen, China) was used for antigen retrieval. Next, 3% bovine serum albumin was used for nonspecific binding blockage, and the sections were incubated with an anti-CHI3L1 antibody at 4° C overnight. Fluorescence images were obtained using an Olympus FV3000 confocal microscope (Olympus, Center Valley, Pa, USA).

The investigators reported that compared with the controls, CHI3L1 serum levels were up-regulated in SA, GA, and AMN groups, while no significant difference was observed in the AUA and ANEN groups. Immunofluorescence revealed that CHI3L1 expression was high in macrophages and adenocarcinoma cells of appendix tissues, but not in the neuroendocrine carcinoma tissues. Moreover, levels of NLR and CRP in the SA and GA groups were considerably higher than in the control group. IL-6 and SAA in SA, GA, ANENs, and AMN groups were also increased compared with the control group. In addition, CHI3L1 displayed good performance in predicting appendicitis, with an AUC of 0.862.

The authors concluded that the patients with appendicitis had an enhanced CHI3L1 expression, associated with increased NLR, CRP, IL-6, and SAA. Moreover, CHI3L1 was crucial in patients with appendiceal neuroendocrine neoplasms. The study was published on November 29, 2022 in the Journal of Clinical Laboratory Analysis.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.